APA (7th ed.) Citation

CT, S., SA, T. D., AA, G., JSF, C., K, Y., K, G., . . . JR, U. (2023). The antianginal ranolazine fails to improve glycaemia in obese liver-specific pyruvate dehydrogenase deficient male mice. Basic & clinical pharmacology & toxicology, 133(2), 194. https://doi.org/10.1111/bcpt.13906

Chicago Style (17th ed.) Citation

CT, Saed, Tabatabaei Dakhili SA, Greenwell AA, Chan JSF, Yang K, Gopal K, Eaton F, Al Batran R, and Ussher JR. "The Antianginal Ranolazine Fails to Improve Glycaemia in Obese Liver-specific Pyruvate Dehydrogenase Deficient Male Mice." Basic & Clinical Pharmacology & Toxicology 133, no. 2 (2023): 194. https://doi.org/10.1111/bcpt.13906.

MLA (9th ed.) Citation

CT, Saed, et al. "The Antianginal Ranolazine Fails to Improve Glycaemia in Obese Liver-specific Pyruvate Dehydrogenase Deficient Male Mice." Basic & Clinical Pharmacology & Toxicology, vol. 133, no. 2, 2023, p. 194, https://doi.org/10.1111/bcpt.13906.